---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-210518"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:29:24.582728+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Angelini Pharma to acquire Catalyst Pharma for $4.1B ($31.50/share), premium 28% to VWAP

## Summary
- All outstanding shares acquired for $31.50 cash per share; total equity value ~$4.1B (21% premium to unaffected close).
- Transaction expected to close Q3 2026, subject to stockholder vote and HSR antitrust clearance.
- Termination fee of ~$155.5M payable by Catalyst under certain conditions; no financing condition.
- Patent litigation with Hetero on FIRDAPSE generic settled; Hetero cannot market before Jan 2035 if approved.
- Directors and executive officers entered voting agreements to support the merger.

## SEC filing metadata
- accession: 0001193125-26-210518
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.01, 5.03, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312526210518/0001193125-26-210518-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312526210518/d90722d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-210518
- JSON: https://secwatch.observer/filing/0001193125-26-210518.json
- Plain text: https://secwatch.observer/filing/0001193125-26-210518.txt

## Source-grounded claims
- claim_id: abddd6e2e8103cdf0d7e74452c3d2d44713f62ce
  claim: CATALYST PHARMACEUTICALS, INC.: Amended Article VIII, Section 8.1 of the By-Laws (Forum Selection Amendment) (effective 2026-05-06).
  evidence_excerpt: On May 6, 2026, the Board of Directors approved and adopted an amendment (the “ Forum Selection Amendment ”) to the Company’s existing By-Laws that amends Article VIII, Section 8.1 of the By-Laws of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1369568/000119312526210518/0001193125-26-210518-index.htm
- claim_id: 913fb8d30d158fe5e5df75d37917794ca87099ed
  claim: CATALYST PHARMACEUTICALS, INC. entered into Agreement and Plan of Merger with Angelini Pharma S.p.A. valued at $31.50 per Share in cash (effective 2026-05-06).
  evidence_excerpt: On May 6, 2026, Catalyst Pharmaceuticals, Inc. (“ Catalyst ” or the “ Company ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Angelini Pharma S.p.A., an Italian Società per azioni (“ Angelini Pharma ” or “ Parent ”), and Angelini Cielo Inc., a Delaware corporation and wholly-owned subsidiary of Parent (“ Merger Sub ”), providing for the merger of Merger Sub with and into the Company (the “ Merger ”), with the Company surviving the Merger as a wholly-owned subsidiary of Parent.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1369568/000119312526210518/0001193125-26-210518-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.